TVM Capital Healthcare has announced a strategic investment in Human Longevity Inc (HLI), a precision medicine company based in the United States. The partnership aims to support HLI’s expansion into Saudi Arabia and Southeast Asia, marking a significant step in the advancement of personalized healthcare in the region.
Human Longevity Inc specializes in integrating genomics and artificial intelligence to offer proactive, data-driven health insights. Through its proprietary Health Nucleus platform, the company provides comprehensive diagnostics that combine whole-genome sequencing with advanced imaging and clinical testing.
The new investment will support HLI in launching clinical facilities in the Middle East and Asia, with a focus on preventive healthcare, longevity, and chronic disease management. Saudi Arabia is a key target market, aligning with the country’s Vision 2030 plan to diversify its economy and enhance healthcare services.
TVM Capital Healthcare, headquartered in Dubai, is known for its focus on impact-driven healthcare investments in emerging markets. The firm’s backing of HLI reflects its commitment to expanding access to next-generation healthcare technologies and services across the region.
The partnership also emphasizes workforce development, with plans to train local healthcare professionals in genomic science and precision diagnostics to support the rollout of HLI’s services.
The move signals growing investor interest in longevity and precision medicine, particularly in regions with evolving healthcare infrastructure and rising demand for preventive solutions.
